Stress hyperglycemia ratio is associated with microcirculatory resistance in patients with ST-segment elevation myocardial infarction

应激性高血糖比值与ST段抬高型心肌梗死患者的微循环阻力相关

阅读:3

Abstract

BACKGROUND: Stress hyperglycemia is a common phenomenon in patients with critical illness, and its association with coronary microcirculation in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI) remains poorly understood. The coronary angiography-derived index of microcirculatory resistance (AMR) is a tool used to assess coronary microcirculation. This study aimed to investigate the relationship between stress hyperglycemia ratio (SHR) and AMR in STEMI patients undergoing pPCI. METHODS: Three hundred sixty-two consecutive patients who underwent pPCI at Taizhou People’s Hospital between 2022 and 2023 were initially screened in this observational study. The study populations were classified as three groups according to fasting SHR tertiles: SHR1: SHR ≤ 0.76 (n = 114); SHR2: 0.76 < SHR < 0.96 (n = 110); and SHR3: SHR ≥ 0.96 (n = 113). Restricted cubic spline analysis was performed to explore the relationship between SHR and AMR. Logistic regression analysis was performed to identify independent predictors of high AMR (AMR ≥ 2.5). RESULTS: A total of 337 STEMI patients were included in this observational study. The AMR was significantly lower in SHR1 and SHR2 than that in SHR3 (all P < 0.05). The AMR were positively correlated with SHR (p for overall < 0.001, p for non-linear = 0.236). Multivariable logistic regression analysis identified SHR3 as an independent risk factor for high AMR after adjusting for other covariates (odds ratio: 1.78, 95% confidence interval: 1.040–3.058, p = 0.035). CONCLUSION: The SHR is an independent predictor of high AMR in STEMI patients undergoing pPCI. These results may offer new insights into the pathophysiology of STEMI and highlight the potential value of SHR as a clinical marker for coronary microcirculation status.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。